The translation of research into the development of innovative and life-saving microbial therapies is set to transform in Australia through a partnership between Hudson Institute of Medical Research and BiomeBank, a clinical stage microbiome therapeutics company.

A Memorandum of Understanding (MoU) between the two organisations has been signed, enabling BiomeBank to bring its experience in the discovery and development of microbial therapies to enable translation of Hudson Institute’s microbiome research.

The partnership strengthens Hudson Institute’s business case for an Australian-first National Centre for Inflammation Research (NCIR) and will initially focus on the development of defined and targeted microbial therapies to treat unmet medical need for patients with Inflammatory Bowel Disease (IBD).

BiomeBank, which has recently launched its Series-A funding round, has signed a four-year collaborative agreement with Hudson Institute to translate current and future microbiome research into microbial therapies. This includes a recent deal granting BiomeBank access to important research on how the microbiota could treat paediatric IBD, which is unique because the research used culturing and high-resolution microbial analysis of the colon rather than stool samples.